Margin resik: Mainz Biomed N.V. (MYNZ)

Logo grafis Mainz Biomed NV (MYNZ)

Mainz Biomed N.V. is implementing advanced molecular tests for early-stage oncology detection. The net profit margin reflects profitability trends, with the current level sitting around 0.00. High margins are driven by cloud-based AI analysis of ColoAlert systems. Profit growth is currently based on European expansion, while FDA certification remains a long-term goal.

mainzbiomed.com (MYNZ) - Margin dodolan resik saka 04.07.2022 nganti 11.03.2026

Rincian metrik komprehensif lan analitis Mainz Biomed N.V. (MYNZ)

- nilai pasar lan prakiraan target analis:
Analisis umum perusahaan:Mainz Biomed N.V., MYNZ
Produk asil prodhuksi Mainz Biomed NV

Mainz Biomed N.V. (MYNZ) revenues depend on the commercial success of its diagnostic tests, specifically ColoAlert. By analyzing the net margin within revenue, an investor assesses the efficiency of converting sales into actual profit. This metric is calculated as the ratio of net income to total revenue, excluding operating expenses. Growth in this ratio confirms the scalability of the business model. Stable positive dynamics serve as a guarantee of the asset's fundamental stability.